美股异动 诺和诺德(NVO.US)涨近6% 因竞争对手礼来(LLY.US)口服减肥药效果不及预期

Group 1 - Novo Nordisk (NVO.US) shares rose nearly 6%, reaching $47.99 as of the report [1] - Eli Lilly (LLY.US) competitor's first small molecule oral GLP-1 drug, Orforglipron, achieved an average weight loss of 11.2%, which is below the expected range of 13% to 15% or more [1]